Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711937 | 0.87 | HCAR2 (0.41) | HTTHSD17B10IDO1L3MBTL1 | |
| SCHEMBL4421954 | 0.77 | HSD17B10 (0.46) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL14189993 | 0.74 | HTT (0.44) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL4421174 | 0.74 | HTT (0.44) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL11782800 | 0.72 | HSD17B10 (0.65) | HTTHSD17B10JUNNFKB1NFKB2 | |
| Ammonia Solution, Strong SCHEMBL11782697 | 0.71 | HSD17B10 (0.63) | HTTHSD17B10JUNNFKB1NFKB2 | |
| SCHEMBL11782702 | 0.70 | HTT (0.40) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL3252305 | 0.68 | HTT (0.37) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL29237010 | 0.68 | HRH4 (0.38) | HTTHSD17B10IDO1HRH4HRH3 | |
| SCHEMBL11219412 | 0.67 | HTT (1.00) | HTTHSD17B10L3MBTL1POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | JOHNSON BARRY L (US) | 2004-01-01 | — | — | US | disclosed |
| US-6593337-B1 | pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002498-A1 | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | POLRMT, TYMP, POLM | HTT 2749/4885HSD17B10 353/4885IDO1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.